Balyasny Asset Management
NGNE icon

Balyasny Asset Management’s Neurogene NGNE Stock Holding History

Balyasny Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7M Buy
818,706
+100,317
+14% +$2.76M 0.03% 604
2026
Q1 		$14.5M Buy
718,389
+109,811
+18% +$2.13M 0.02% 838
2025
Q4 		$12.5M Sell
608,578
-90,424
-13% -$2.25M 0.02% 926
2025
Q3 		$12.1M Buy
+699,002
New +$14M 0.02% 955
2020
Q4 		– Sell
-5,500
Closed -$1.32M – 1581
2020
Q3 		$1.32M Buy
5,500
+2,000
+57% +$484K 0.01% 941
2020
Q2 		$1.16M Buy
3,500
+2,590
+285% +$675K 0.01% 802
2020
Q1 		$207K Sell
910
-4,127
-82% -$849K ﹤0.01% 1047
2019
Q4 		$1.24M Buy
+5,037
New +$502K 0.01% 846

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management's NGNE Position: Q2 2026 in Review

Balyasny Asset Management increased its Neurogene (NGNE) stake by 14% in Q2 2026, buying an estimated $2.76M and bringing the position to 818,706 shares worth $25.7M. The position accounts for 0.03% of the portfolio, ranked #604.

Balyasny Asset Management first reported a position in NGNE in Q4 2019 and has held it in 8 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Balyasny Asset Management held 818,706 shares of Neurogene worth $25.7M as of Q2 2026.
  • Balyasny Asset Management bought 100,317 Neurogene shares in Q2 2026, an estimated $2.76M.
  • Neurogene made up 0.03% of Balyasny Asset Management's portfolio in Q2 2026, its #604 holding.
  • Balyasny Asset Management first reported a position in Neurogene in Q4 2019 and has held it in 8 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.